213250-60-3

Basic information

• Product Name: Cyclohexanemethanol, 3,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-hydroxy-4-methylene-, (3R,5R)-
• Synonyms: [(3'R,5'R)-3',5'-Bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4'-methylenecyclohexyl]methanol;[(3R,5R)-3,5-Bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-methylenecyclohexyl]methanol;(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-1-hydroxymethyl-4-methylene-cyclohexanol;[(3R,5R)-3,5-Bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy4-methylenecyclohexyl]methanol
• CAS NO: 213250-60-3
• Molecular Formula: C20H42O4Si2
• Molecular Weight: 402.722
• Mol File: 213250-60-3.mol
• Article Data: 27

Chemical Properties

• CAS DataBase Reference: Cyclohexanemethanol, 3,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-hydroxy-4-methylene-, (3R,5R)-(CAS DataBase Reference)
• NIST Chemistry Reference: Cyclohexanemethanol, 3,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-hydroxy-4-methylene-, (3R,5R)-(213250-60-3)
• EPA Substance Registry System: Cyclohexanemethanol, 3,5-bis[[(1,1-dimethylethyl)dimethylsilyl]oxy]-1-hydroxy-4-methylene-, (3R,5R)-(213250-60-3)

Safety Data

• Hazardous Substances Data: 213250-60-3(Hazardous Substances Data)

Upstream product

• 304-59-6 Rochelle's salt 
• 213250-59-0 methyl (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-methylenecyclohexanecarboxylate 
• 213250-58-9 (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-1-hydroxy-4-oxocyclohexanecarboxylic acid methyl ester 
• 135711-62-5 methyl quinicate 
• 77-95-2 D-(-)-quinic acid 

Downstream Products

• 213250-61-4 (3R,5R)-3,5-bis[(tert-butyldimethylsilyl)oxy]-4-methylenecyclohexanone 
• 213250-63-6 2-((3R,5R)-3,5-bis(tertbutyldimethylsilyloxy)-4-methylenecyclohexylidene)ethanol 
• 213250-62-5 methyl-2-((3R,5R)-3,5-bis(tertbutyldimethylsilyloxy)-4-methylenecyclohexylidene)acetate 
• 213250-64-7 [2-[(3'R,5'R)-3',5'-bis[(tert-butyldimethylsilyl)oxy]-4'-methylenecyclohexylidene]ethyl]diphenylphosphine oxide 
• 213250-65-8 (1R,3R,7E,17β)-1,3-bis{[tert-butyl(dimethyl)silyl]oxy}-2-methylidene-17-{6-methyl-6-[(triethylsilyl)oxy]heptan-2-yl}-9,10-secoestra-5,7-diene 
• 213250-69-2 (1R,3aS,7aR)-4-[2-[(3R,5R)-3,5-Bis-(tert-butyl-dimethyl-silanyloxy)-4-methylene-cyclohexylidene]-eth-(E)-ylidene]-1-((S)-1,5-dimethyl-5-triethylsilanyloxy-hexyl)-7a-methyl-octahydro-indene 
• 213319-29-0 2-methylidene-19-nor-1α,25-dihydroxyvitamin D3 
• 213250-70-5 (20S)-2-methylene-19-nor-1α,25-dihydroxyvitamin D₃ 
• 852658-50-5 2-methylene-19,21-dinor-1α-hydroxybishomopregnacalciferol 
• 852658-44-7 (20R)-1alpha-Hydroxy-2-methylene-19-nor-bishomopregnacalciferol 
• 852658-46-9 2-Methylene-(20S)-19-nor-1alpha-hydroxy-trishomopregnacalciferol 
• 852658-66-3 C₃₅H₆₄O₂Si₂ 

Relevant articles and documents

Synthesis of 2-ethyl-19-nor analogs of 1α,25-dihydroxyvitamin D 3

The synthesis of two new A-ring precursors, useful for the convergent assembly of 2α-ethyl and 2β-ethyl derivatives of 19-nor-1α,25- dihydroxyvitamin D3, is described. These building blocks were prepared in 14 steps from quinic acid, which led to a new and practical synthesis of 2α-ethyl-14-epi-19-nor-20-epi-23-yne-1,25(OH) 2D3, an analog that shows a remarkably low calcemic effect in mice, while retaining the ability to promote cell differentiation and to inhibit cell proliferation in a number of human cancer cell lines. Two new phosphanone building blocks, useful for the stereocontrolled synthesis of 2-ethyl-substituted 19-nor analogs of 1α,25-dihydroxyvitamin D 3, were prepared from quinic acid. This route offers an attractive practical solution for the introduction of these synthetically challenging but highly interesting A-ring modifications. Copyright

Vitamin D analogs for obesity prevention and treatment

Methods for treating and preventing obesity, inhibiting adipocyte differentiation, inhibiting increased SCD-1 gene transcription, and/or reducing body fat in a subject include administering at least one analog of 1α,25-dihydroxyvitamin D3 or 1α

2-Alkylidene-19-nor-vitamin D derivatives for the treatment of osteosarcoma

The present invention relates to methods of treating osteosarcoma, the methods comprising administering to a patient in need thereof a 2-alkylidene-19-nor-vitamin D derivative. Particularly, the present invention relates to methods of treating osteosarcom